Xtandi Combo Fails to Improve Survival in Advanced Prostate Cancer Patients in Phase 4 Study December 19, 2016 Pfizer and Astellas Pharma announced that a Phase 4 clinical trial, investigating longer-term use of Xtandi (enzalutamide) as a combination treatment for patients with metastatic castration-resistant prostate cancer (mCRPC), did not reach its primary goal of improved progression-free survival. The trial is concluding but data will continue to be evaluated, the companies said.Top-line results failed to show that continued treatment with Xtandi, in combination with the chemotherapy drugs Zytiga (abiraterone acetate) and prednisone, led to better progression-free survival in chemotherapy-naive mCRPC patients whose PSA levels had progressed despite previous Xtandi therapy. Read more.Source: Prostate Cancer News Today Prostate Cancer News
Pfizer and Astellas Pharma announced that a Phase 4 clinical trial, investigating longer-term use of Xtandi (enzalutamide) as a combination treatment for patients with metastatic castration-resistant prostate cancer (mCRPC), did not reach its primary goal of improved progression-free survival. The trial is concluding but data will continue to be evaluated, the companies said.Top-line results failed to show that continued treatment with Xtandi, in combination with the chemotherapy drugs Zytiga (abiraterone acetate) and prednisone, led to better progression-free survival in chemotherapy-naive mCRPC patients whose PSA levels had progressed despite previous Xtandi therapy. Read more.Source: Prostate Cancer News Today
